CRISPR Therapeutics AG
CRSP CH0334081137
CRISPR Therapeutics AG is a SwissAmerican biotechnology company headquartered in Zug, Switzerland. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award award in 2022. The companys lead program, exagamglogene autotemcel, or exa-cel
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -52% | -49% | 53% | -40% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Kulkarni Samarth CEO |
58.15 USD |
13,081 Sold |
760,660 USD |
16/08/2025 | 18/08/2025 |
| Treco Douglas A |
57.03 USD |
20,000 Bought |
1,140,600 USD |
06/08/2025 | 06/08/2025 |
| George Simeon |
52.03 USD |
6,510 Bought |
338,715 USD |
16/07/2025 | 16/07/2025 |
| George Simeon |
52.03 USD |
22,319 Bought |
1,161,258 USD |
16/07/2025 | 16/07/2025 |
| George Simeon |
52.03 USD |
960,983 Bought |
49,999,945 USD |
16/07/2025 | 16/07/2025 |
| Patel Naimish CMO |
35.94 USD |
3,932 Sold |
141,316 USD |
28/05/2025 | 29/05/2025 |
| Kasinger James R. SR OFF |
41.23 USD |
3,185 Sold |
131,318 USD |
20/03/2025 | 21/03/2025 |
| Bruno Julianne COO |
41.23 USD |
1,714 Sold |
70,668 USD |
20/03/2025 | 21/03/2025 |
| Kulkarni Samarth CEO |
41.23 USD |
10,031 Sold |
413,578 USD |
20/03/2025 | 21/03/2025 |
| Prasad Raju CFO |
41.23 USD |
2,197 Sold |
90,582 USD |
20/03/2025 | 21/03/2025 |